The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of rheumatoid arthritis, systemic lupus erythematosus, and other inflammatory conditions is…
